Myriad Genetics, Inc. (MYGN)

Genetic testing laboratory, FTE count. Read November 9, 2026 from the annual report for the period ending December 31, 2025, filed February 24, 2026. Ranked 55 of the 145 Healthcare companies read so far, by the share within reach now.

The filing states approximately 2,700 full-time equivalent employees at December 31, 2025 and describes one genetic testing business with no count by function, so the whole workforce is read at medical and diagnostic laboratories by description.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 34% now, 39% at the end of 2027, 41% at the end of 2028, 41% at the end of 2030. By the patterns, the work is about 41% desk work, 19% people work and 40% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 60% of the working time stays with people (conversation, in-person and hands-on work), 33% becomes checking a model's work and 6% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

2,700 employees as of December 31, 2025 (full-time equivalent). Not stated; the excerpt gives no count by country.

The filing: “As of December 31, 2025, we had approximately 2,700 full-time equivalent employees.”

The workforce as industry patterns

What the filing says about the workforce: Approximately 2,700 full-time equivalent employees at December 31, 2025; voluntary turnover 10% in 2025; about 65% women; no collective bargaining agreement; eight employee resource groups; 84% rated it a Great Place to Work in 2025.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Medical and Diagnostic Laboratories, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five. Now is projected from METR's April 2026 measurement and Epoch's November 2026 index.

• Labcorp Holdings Inc. (LH, 71,000 employees)35% now, 45% by 2028
• Quest Diagnostics Incorporated (DGX, 57,000 employees)34% now, 41% by 2028
• RadNet, Inc. (RDNT, 11,264 employees)34% now, 41% by 2028
• Natera, Inc. (NTRA, 6,140 employees)34% now, 41% by 2028
• Lumexa Imaging Holdings, Inc. Common Stock (LMRI, 5,019 employees)34% now, 41% by 2028
• Tempus AI, Inc. (TEM, 3,800 employees)39% now, 51% by 2028
• Guardant Health, Inc. (GH, 2,506 employees)34% now, 41% by 2028
• NeoGenomics, Inc. (NEO, 2,500 employees)34% now, 41% by 2028

What the filing says about AI

24 sentences in the filing name AI. The filing describes a collaboration with PATHOMIQ for exclusive U.S. rights to an AI-enabled prostate cancer diagnostic platform, with an AI-enabled prostate cancer test in development for launch in the first half of 2026.

• “In early 2025, we entered into a strategic collaboration with PATHOMIQ, Inc. pursuant to which we obtained exclusive U.S. licen sing rights to PATHOMIQ's AI-enabled diagnostic platform, PATHOMIQ_PRAD, to enhance our oncology portfolio and offer AI-driven prognostic and predictive solutions for prostate cancer care.”
• “Prostate Cancer and Artificial Intelligence Development ◦ We advanced development of an AI-enabled prostate cancer diagnostic test in collaboration with PATHOMIQ Inc., with an anticipated commercial launch of the test in the first half of 2026.”
• “We believe key industry trends include the following: acceleration of personalized, preventive, and home-based care models supported by advances in telemedicine, remote monitoring, and digital engagement; growing consumer demand for clinically validated and accessible genetic testing solutions that support early detection, therapy selection, and proactive disease prevention; increased focus on...”
• “Our competitors in women's health include Natera, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, BillionToOne, Inc., Tempus AI, Inc., Fulgent Genetics, Inc., and Peekaboo Early Detection Gender DNA Test.”
• “Our competitors in this market include Genomind, Tempus AI, Inc., Quest Diagnostics Incorporated, and Laboratory Corporation of America Holdings.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20211median 0
• Fiscal 20221median 0
• Fiscal 20231median 1
• Fiscal 202413median 4
• Fiscal 202524median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The headcount is a full-time equivalent figure (rule 2).
• The U.S. share is not stated.
• No count by function; one pattern by description (c).

Source: the company's annual report on EDGAR, accession 0000899923-26-000018, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.